Subcutaneous mass as the primary manifestation of gestational choriocarcinoma: A case report  by Cheng, Wen-Fang et al.
Gynecologic Oncology Reports 2 (2012) 11–13
Contents lists available at SciVerse ScienceDirect
Gynecologic Oncology Reports
j ourna l homepage: www.e lsev ie r .com/ locate /gynorCase Report
Subcutaneous mass as the primary manifestation of gestational choriocarcinoma:
A case report
Wen-Fang Cheng a,b,c,⁎, I-Hui Chen a, Kuan-Ting Kuo d, Li-Hui Tseng e, Chi-An Chen a
a Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan
b Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
c Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
d Department of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan
e Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwana r t i c l e i n f oArticle history:
Received 25 August 2011
Available online 26 October 2011
Keywords:
Choriocarcinoma
Gestation
Pregnancy
Chemotherapy1. Introduction
Choriocarcinoma is a highly malignant trophoblastic tumor com-
posed of two types of cells, syncytiotrophoblasts and cytotrophoblasts
(Seckl et al., 2010). Its incidence is reported variously from 1 in 13,
000 to 50,000 pregnancies (Alveyn and Loehry, 1988). Metastasis is
most often associated with choriocarcinomas in contrast to other vari-
ants of the GTT (Berkowitz and Goldstein, 1996). Choriocarcinoma
commonly metastasizes to the lungs and vagina, and less commonly,
to the liver, brain, kidneys and gastrointestinal tract (Bagshawe,
1992). Vaginal bleeding, abdominal swelling, amenorrhea, chest and
neurological symptoms are themost common presentations depending
on the extent of the disease, but by far the commonest symptom is vag-
inal bleeding, a consequence of the tumor invading the uterus (Chama
et al., 2002).
To the best of our knowledge, there was no choriocarcinoma with
clinical presentation of subcutaneous metastasis reported in the liter-
ature. An abdominal subcutaneous mass as the primary manifestation
of choriocarcinoma is extremely rare and difﬁcult for diagnosis. Here
we reported a case of gestational choriocarcinoma with the primary
manifestation of subcutaneous metastasis 10 years after her last preg-
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nary nodules by image studies. Wide excision of the abdominal tumor
revealed that the tumor cells were positive for cytokeratin and human
chorionic gonadotropin by immunohistochemical stainings. DNA poly-
morphism analysis revealed that the tumor cells possessed both geno-
mic DNA alleles from the patient and her husband. Gestational
choriocarcinoma was ﬁnally diagnosed. The serum level of β-hCG in
the patient was 382 mIu/ml after surgery. So the EMA-CO chemothera-
peutic regimens (etoposide, methotrexate, and actinomycin, followed
by cyclophosphamide and vincristine)were given. The patient achieved
clinical remission for 7 months after chemotherapy. Subcutaneousmass
can be the ﬁrst manifestation of choriocarcinoma. Choriocarcinoma
should be the differential diagnosis for special manifestation of
women in reproductive ages.2. Case report
A 49-year-oldwomanpalpated a rapid growingmass over lower ab-
domen for three months. Her menstrual cycles became irregular since
2 months ago. The patient had conceived 7 times with 4 miscarriages
and her three children were all delivered through cesarean section.
Her last cesarean section was 20 years ago and her last pregnancy was
artiﬁcial abortion 10 years ago.
Pelvic examination revealed a smooth cervix, and normal size of uter-
us and bilateral adnexae. Amultiloculatedmasswhichwas around base-
ball size within the abdominal wall was noted. The subcutaneous mass
located nearby the wound of the cesarean section with intact abdominal
skin. Transabdominal ultrasonography revealed a multilocular tumor
measuring 8×6×5 cm located behind the cesarean scar and within the
lower anterior subcutaneous layer. No abnormal ﬁnding was identiﬁed
in the endometrial cavity, uterus and bilateral ovaries. Magnetic reso-
nance imaging (MRI) study showed a large inﬁltrative and heteroge-
neous mass, measured around 14 cm in largest dimension, and located
within the anterior pelvis wall (Fig. 1). Computed tomography (CT)
study showed bilateral multiple pulmonary nodules. Subcutaneous ma-
lignancy with pulmonary metastases was suspected. Biopsies of the ab-
dominal wall tumor were undergone and the pathologic report
revealed a poorly-differentiated squamous cell carcinoma. Immunohis-
tochemically, the tumor cells were positive for cytokeratin (AE1/AE3)
and p63 but negative for vimentin, CD31, CD34, S-100 protein, calretinin
Fig. 1.Magnetic resonance imaging study of the abdomen was performed before surgery,
revealing a large inﬁltrative and heterogeneous mass around 14 cm in largest dimension,
located within the anterior pelvis wall. (Arrow pointed the subcutaneous mass).
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without deﬁnite origin was impressed. Comprehensive surveillance
such as anal digital and oro-pharyngeal physical examination, endocervi-
cal curettage, panendoscope and colonoﬁberoscope, were performed
with negative results. Positron emission tomography (PET) with F18-
ﬂuorodeoxyglucose revealed multiple viable hot spots at the anterior
lower abdominal wall and bilateral lungs (Fig. 2). Local excision of the
abdominal tumorwas then undergone. The tumor locatedwithin the an-
terior pelvis wall with involving the bilateral abdominal rectal muscles.
The tumorwas totally excised and then the abdominal wall was repaired
directly with artiﬁcial mesh. Microscopically, the tumor cells were char-
acteristic of sheets and nests of hyperchromatic and pleomorphic tumor
cells containing vesicular nuclei, distinct nucleoli and medium amounts
of eosinophilic cytoplasm. There are multinuclear giant cells similar toFig. 2. Positron emission tomography with F18-ﬂuorodeoxyglucose revesyncytiotrophoblasts bordering the tumor nests, creating two cell pat-
terns. The tumor cells were diffusely positive for cytokeratin (AE1/
AE3), negative for p16 and human placental lactogen (hPL), but strongly
positive for the human chorionic gonadotropin (hCG) and HSD3B1 by
immunohistochemical stainings (Fig. 3). The serum level of β-hCG in
the patient was 382 mIu/ml after surgery. Choriocarcinoma of FIGO
stage IV with subcutaneous and pulmonary metastases was diagnosed.
To further diagnose if this is a gestational or non-gestational cho-
riocarcinoma, the patient's and her husband's peripheral blood
mononuclear cells (PBMCs), and the choriocarcinoma tissues were
checked by DNA polymorphism analysis. All of the 16 foci analyzed
in the choriocarcinoma tissues possessed both genomic DNA alleles
from the patient and her husband. The gestational choriocarcinoma
was ﬁnally diagnosed.
The EMA-CO chemotherapeutic regimens (etoposide, methotrex-
ate, and actinomycin, followed by cyclophosphamide and vincristine)
for a total of nine courses were given including 2 more courses after
her serum level of β-hCG being less than 6.15 mIu/ml after 7 courses
of EMA-CO regimens. Abdomino-pelvic CT studies revealed no resid-
ual lesions in the abdominal wall and lungs. At 7 months after treat-
ment, the patient remains disease-free.
3. Discussion
The molecular mechanism behind the long latent period between
development of a choriocarcinoma and last pregnancy has not been de-
scribed. Gestational choriocarcinoma is a rare complication of pregnan-
cy and usually arises from a prior molar pregnancy or rarely a non-
molar gestation, within one year of the antecedent pregnancy (O'Neill
et al., 2008). However, Tsukamoto et al. reported three postmenopausal
patients with choriocarcinoma, with the periods between the last preg-
nancy and development of tumor being 11, 15 and 18 years (Tsukamoto
et al., 1985). Our patient who still had menstruation had her last preg-
nancy with artiﬁcial abortion 10 years ago. There was no abnormal
lesion within the endometrial cavity or in the myometrium. Based on
the clinical ﬁndings, we propose that there were residual trophoblastic
and/or syncytiotrophoblastic cells which were dropped in the subcuta-
neous layer during her last cesarean section. These residual and ectopic
trophoblastic and/or syncytiotrophoblastic cells started proliferation
rapidly when the patient's hormone status changed. Another possibilityaled multiple viable hot spots at the anterior lower abdominal wall.
Fig. 3. (A) The tumor cellswere characteristic ofmultinucleated, pleomorphic cellswith hyperchromatic nuclei and abundant eosinophilic cytoplasm byH&E stain (10×20). Hemorrhage
can be also seen within the tumor. (B) The tumor cells showed diffusely and strongly positive human chorionic gonadotropin staining by immunohistochemistry (10×20).
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the uterine scar of the prior cesarean section hadmalignant transforma-
tion and then metastasized to the subcutaneous tissues of the abdomi-
nal wall.
When choriocarcinoma occurs in a rare place like subcutaneous
tissues for this patient, non-gestational origin should be ruled out.
Nongestational choriocarcinoma (NGCO) is thought to arise from
germ cells and is characterized by its presentation in males and chil-
dren. The NGCO has worse prognosis so more aggressive therapy with
multiple chemotherapeutic agents is required (Jacobs et al., 1982).
Genetic analyses provide an excellent tool to identify the nongesta-
tional and gestational choriocarcinoma cases like our patient. The
DNA polymorphism analysis revealed that the choriocarcinoma
tissues of our case possessed both of patients and her husband's geno-
mic DNA. So we chose the chemotherapeutic regimens for gestational
choriocarcinoma to treat the patient. The gestational choriocarcinoma
was ﬁnally diagnosed.
The subcutaneous tumor is a very rare primary manifestation of
gestational choriocarcinoma. We presented a very rare case of gesta-
tional choriocarcinoma presenting subcutaneous tumor without the
other symptoms or signs. Subcutaneous metastasis is a very rare met-
astatic site of gestational choriocarcinoma. Vaginal bleeding, abdomi-
nal swelling, amenorrhea, chest and neurological symptoms are the
most common presentations depending on the extent of the disease,
but by far the commonest symptom is vaginal bleeding, a conse-
quence of the tumor invading the uterus. Choriocarcinoma commonly
metastasizes to the lungs and vagina, and less commonly, to the liver,
brain, kidneys and gastrointestinal tract. Chama et al. (2002) reported
a case of gestational choriocarcinoma with cutaneous metastasis
on the chest wall. Cutaneous metastasis is a rare presentation of
choriocarcinoma and a poor prognostic sign because it occurs only
with widespread disease. However, only subcutaneous and pulmo-
nary metastases were observed in our patient.The diagnosis of choriocarcinoma is based on the surgical specimens
with special stainings such as hPL and hCG. Choriocarcinoma was mis-
diagnosed as poorly-differentiated squamous cell carcinoma for this
patient. Most cases of choriocarcinoma are intra-uterine and of gesta-
tional origin. The non-gestational choriocarcinomas are believed to de-
velop from pluripotent germ cells, most commonly arising in the
gonads. Various poorly differentiated carcinomas can also show focal
area of choriocarcinomatous differentiation. The special staining such
as cytokine and hCG for choriocarcinoma plays an important role on
the differential diagnosis of choriocarcinoma, poorly-differentiated
carcinoma and sarcoma. And hPL can differentiate the placental site
trophoblastic tumor (PSTT) and choriocarcinoma. Most important is
that gestational choriocarcinoma should be always into consideration
for women of reproductive ages with unusual presentations.
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